← FDA DRUG APPROVALS

FDA NDA · NDA216513

PHEBURANE

sodium phenylbutyrate

Sponsor: MEDUNIK

APPLICATION
NDA216513
TYPE
NDA
ORIGINAL APPROVAL
2022-06-17
LATEST ACTION
2026-07-16
ROUTE
ORAL
DOSAGE FORM
PELLETS
MARKETING STATUS
Prescription

Products

PHEBURANE · ReferencePrescription
SODIUM PHENYLBUTYRATE 84GM/BOT · PELLETS · ORAL

Approval history

2026-07-16Labeling · Supplement 7 · standardLetterAP
2022-06-17Type 5 - New Formulation or New Manufacturer · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →